EYE-GO Secures Strategic Investment from Topcon Healthcare

EYE-GO, a Danish MedTech company, today announced that Topcon Healthcare, Inc will become a strategic investor in their company. According to EYE-GO, the collaboration reflects a shared vision to revolutionize chronic eye disease management through evidence-based diagnostic insights, product innovation, and technology. 

“We are thrilled to welcome Topcon Healthcare as a strategic investor and partner,” Christian Stig Møller, Chairman of EYE-GO, said in a recent press release. “In Topcon Healthcare, we’ve found not only a leading force in eyecare technology, but also a visionary partner in the digital health space. This strategic partnership also strengthens the EYE-GO board of directors with the appointment of Ali Tafreshi, Topcon Healthcare, Inc. CEO & President, and Robert N. Weinreb, MD, Distinguished Professor of Ophthalmology, University of California, San Diego.”

Topcon Healthcare’s investment will support the development of the MistGo® Digital, a new microdosing drug delivery system with a digital adherence monitoring platform. The system sends patients reminders to administer medications, verifies correct usage, and shares real-time adherence data with clinicians. Under the agreement, MistGo® Digital will be integrated into Topcon Healthcare’s Harmony® digital health information platform.

“Digital technology is transforming eye care, and MistGo® Digital represents a leap forward in how therapies are delivered and monitored,” said Ali Tafreshi, CEO of Topcon Healthcare, Inc. “EYE-GO’s innovation complements our vision of connected care pathways. Adding an intelligent therapeutic solution enhances the patient experience, improves outcomes, and supports a more data-driven future for eye care.”